Paris, France, October 31st, 2023
Voisin Consulting Life Sciences (VCLS), a prominent global HealthTech solution provider offering end-to-end solutions from preclinical to post-launch, announced today the acquisition of MedEngine, a leading medical science agency in the Nordics. This results in the creation of one of the world’s most comprehensive scientific hubs for innovative therapies, serving a broad range of developers and investors in life sciences.
The acquisition unites two companies with highly complementary service offerings, both sharing a commitment to scientific excellence, individual empowerment, and a dedication to enhancing patient outcomes through continuous innovation. VCLS’s services span from the pre-clinical development stage to post-approval regulatory services. Synergistically, MedEngine’s expertise begins at real-world evidence generation and market access, extending across all post-marketing medical and commercial phases.
“The acquisition strengthens VCLS’s digital capabilities and facilitates versatile use of RWD, for example, to support market access efforts and the creation of virtual control arms in clinical studies”, says Dr. Emmanuelle Voisin, Founder and CEO of VCLS.
This strategic merger positions the VCLS group as one of the most comprehensive platforms, providing science-driven interdisciplinary solutions in science and technology, regulatory science, market access, real-world evidence, and commercialization services. These services enable innovators in Biotech, Pharma, MedTech and digital health to thrive in their competitive markets.
“We have strategically built MedEngine as the Nordic leader in evidence generation, market access, and scientific content creation — and we are excited about this new chapter in our journey. We believe that this partnership is a perfect strategic fit, ensuring a promising future for our talented team as they become part of a company that shares our values and vision for innovation and growth,” says Tero Ylisaukko-oja, Founder and CEO of MedEngine.
MedEngine will retain its brand identity, continuing to oversee and develop its Market Access, Medical Data Science, and Scientific Content Solutions business segments globally. The transaction will open unique opportunities for existing and future clients through the expanded range of services offered by the VCLS group.
About VCLS
Founded in 1997, VCLS provides end-to-end HealthTech solutions, to support biotechnology, pharmaceutical and MedTech manufacturers throughout their product development. From early-stage development through to post-launch and beyond, VCLS assists innovators by designing product development strategies and conducting clinical trials that optimize clinical development to drive commercial success.
The integrated solutions encompass clinical research, vigilance, regulatory strategy & submissions, chemistry manufacturing & control (CMC) and market access. With offices in the US, France, UK, Switzerland, Denmark, Madagascar, India and China, VCLS serves a broad range of developers and investors in HealthTech.
For more information, please visit www.voisinconsulting.com
About MedEngine
MedEngine is a digitally minded, premium service provider for the pharmaceutical industry, built upon extensive academic expertise and years of experience in the industry. MedEngine creates strategic solutions by combining Medical Data Science, Market Access, and Scientific Content Solutions that accelerate the future of care.
Founded in 2014, MedEngine has a strong presence across the Nordic countries with offices in Helsinki (Finland), Copenhagen (Denmark), and Stockholm (Sweden). Employing nearly 40 scientifically trained professionals and supported by an extensive scientific network throughout the region, MedEngine’s customer base includes the regional affiliates and global teams of some of the world’s leading pharmaceutical companies.
For more information, please visit www.medengine.fi
Media contact:
Zhengxi Danard
Marketing Director, VCLS
+33 1 41 31 89 90
